What is Vyleesi (bremelanotide) and how is it used for treating hypoactive sexual desire disorder in adult pre‑menopausal women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Vyleesi

Vyleesi (bremelanotide) is an FDA-approved, self-administered subcutaneous injection specifically indicated for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women—characterized by low sexual desire causing marked distress or interpersonal difficulty that is NOT due to medical/psychiatric conditions, relationship problems, or medication effects. 1

Mechanism and Pharmacology

Vyleesi is a melanocortin receptor agonist, specifically a synthetic peptide analogue of alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor, which modulates brain pathways involved in sexual response 2. This central nervous system mechanism distinguishes it from hormonal approaches.

Dosing and Administration

The recommended dose is 1.75 mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity 1. Critical dosing parameters include:

  • Maximum frequency: One dose per 24 hours
  • Monthly limit: No more than 8 doses per month recommended
  • Trial period: Discontinue after 8 weeks if no symptom improvement 1

The duration of efficacy after each dose remains incompletely characterized, so patients should determine optimal timing based on their individual response to desire enhancement and tolerability of adverse effects 1.

Efficacy Evidence

The two pivotal Phase 3 RECONNECT trials (studies 301 and 302) demonstrated statistically significant improvements in both coprimary endpoints compared to placebo 3:

  • Sexual desire improvement (Female Sexual Function Index-desire domain): Integrated studies showed 0.35-point increase (P<.001)
  • Distress reduction (Female Sexual Distress Scale item 13): Integrated studies showed -0.33-point reduction (P<.001)

Long-term data from the 52-week open-label extension showed sustained improvements, with desire domain scores increasing 1.25-1.30 points and distress scores decreasing -1.4 to -1.7 points from baseline in patients continuing bremelanotide 4. A recent 2026 meta-analysis confirmed that bremelanotide improves both desire and arousal subscales as well as total FSFI scores 5.

Safety Profile and Adverse Events

The most common adverse events from the integrated Phase 3 studies were 6:

  • Nausea: 40.0% (vs. 1.3% placebo) - most common reason for discontinuation
  • Flushing: 20.3% (vs. 1.3% placebo)
  • Headache: 11.3% (vs. 1.9% placebo)
  • Injection site reactions: 5.4% (vs. 0.5% placebo)

Most adverse events were mild to moderate in intensity. Across the entire clinical development program involving 3,500 subjects in 43 studies, there were no deaths and few serious adverse events 6.

Critical Warnings and Contraindications

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease 1. This stems from predictable hemodynamic effects:

  • Blood pressure increases: Maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2-4 hours post-dose
  • Heart rate reduction: Up to 5 beats per minute decrease
  • Duration: Effects typically resolve within 12 hours 1

Focal hyperpigmentation is a specific risk, particularly with frequent dosing. While rare when following label recommendations (≤8 doses/month), it occurred in over one-third of subjects receiving 16 consecutive daily doses 6. This underscores the importance of adhering to monthly dosing limits.

Clinical Context and Limitations

Vyleesi is NOT indicated for:

  • Postmenopausal women
  • Men
  • Enhancing sexual performance 1

Important clinical caveat: Flibanserin and bremelanotide have not been evaluated in women with cancer history or those on endocrine therapy 7. The ASCO guidelines note uncertainty regarding the risk/benefit ratio in these populations 7.

Place in Therapy

Vyleesi represents one of only two FDA-approved pharmacological options for HSDD in premenopausal women (the other being flibanserin, a daily oral medication). Recent evidence suggests combining medical and psychological approaches may be optimal 8, though the 2026 meta-analysis found that bremelanotide specifically improves desire, arousal, and reduces distress as monotherapy 5.

Key clinical advantage: On-demand dosing allows patients to use medication only when desired, unlike daily flibanserin. However, the clinical benefit, while statistically significant, may be modest 9, and patient selection should involve shared decision-making about expectations and tolerability, particularly regarding nausea.

Related Questions

What is the recommended dosing regimen, contraindications, and monitoring requirements for bremelanotide (used to treat acquired generalized hypoactive sexual desire disorder in premenopausal adults)?
What is the recommended protocol for subcutaneous bremelanotide administration in a premenopausal adult woman with hypoactive sexual desire disorder, including eligibility criteria, dosing, injection technique, site rotation, monitoring, and contraindications?
What is the relationship between PT-141 (Bremelanotide) and subsequent cough?
How do bremelanotide and flibanserin affect sexual desire in premenopausal women with hypoactive sexual desire disorder, and what outcome measures (Female Sexual Function Index desire domain, Female Sexual Distress Scale, and number of satisfying sexual events) are used to assess their efficacy?
In a premenopausal woman with acquired generalized hypoactive sexual desire disorder, can buspirone (a 5‑HT1A partial agonist) be used as a first‑line or approved therapy?
What is the appropriate management of pityriasis alba in a 2‑year‑old, including the use of topical tacrolimus?
How should a patient with a serum 25‑hydroxyvitamin D level of 16.95 ng/mL be managed?
What type‑specific confirmatory test should be ordered for a patient with a positive HSV‑1 and HSV‑2 antibody screen?
What is the recommended repletion and maintenance regimen for an 80-year-old patient with a serum 25‑hydroxyvitamin D level of 16.9 ng/mL after previous vitamin D supplementation?
In a patient with seizures, neurobehavioral regression, daily vomiting, hyperphagia, intellectual disability, and iron deficiency, whose intact parathyroid hormone, thyroid‑stimulating hormone, and free thyroxine are all normal, what are the appropriate next diagnostic and management steps?
In a 65-year-old patient with left ankle swelling that worsens at night, what is the appropriate next step in management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.